3 suspended. 3 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Suspended 3 |
| Phase 2 | 1 | Suspended 1 |
Follow Demyelinating Diseases: new trials by email Literature Review of Demyelinating Diseases trials Research Report on Demyelinating Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| IDP-023 g-NK Cells Plus Ocrelizumab in Patients With Progressive Multiple Sclerosis IDP-023, Ocrelizumab, Interleukin-2 - Multiple Sclerosis, Primary Progressive Multiple Sclerosis (PPMS) | Phase 1 | Suspended | Indapta Therapeutics, INC. | 34 | 2026-06-30 | 2025-04-30 |
| Study of Safety, Tolerability and Efficacy of PBKR03 in Pediatric Subjects With Early Infantile Krabbe Disease PBKR03 - Leukodystrophy, Globoid Cell | Phase 1 / Phase 2 | Suspended | Gemma Biotherapeutics | 24 | 2022-02-24 | 2026-06-30 |
| Tracking Peripheral Immune Cell Infiltration of the Brain in Central Inflammatory Disorders Using [Zr-89]Oxinate-4-labeled Leukocytes. [Zr-89]Oxine-labeled leukocytes PET/MRI - Fibromyalgia, Chronic Fatigue Syndrome | Phase 1 | Suspended | University of Alabama at Birmingham | 120 | 2021-10-05 | 2026-06-02 |
Multiple Sclerosis (2) · Autoimmune Diseases (1) · Autoimmune Diseases of the Nervous System (1) · Demyelinating Autoimmune Diseases, CNS (1) · Fatigue Syndrome, Chronic (1) · Fibromyalgia (1) · Immune System Diseases (1) · Leukodystrophy, Globoid Cell (1) · Lysosomal Storage Diseases (1) · Multiple Sclerosis, Chronic Progressive (1) · Nervous System Diseases (1) · Rare Diseases (1)
Disease Attributes (3) · Pathologic Processes (3) · Pathological Conditions, Signs and Symptoms (3) · Brain Diseases (2) · Central Nervous System Diseases (2) · Chronic Disease (2) · Leukoencephalopathies (2) · Nervous System Diseases (2) · Autoimmune Diseases (1) · Autoimmune Diseases of the Nervous System (1) · Brain Diseases, Metabolic (1) · Brain Diseases, Metabolic, Inborn (1) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1) · Demyelinating Autoimmune Diseases, CNS (1)
Cyclophosphamide (1) · Interleukin-2 (1) · Mesna (1) · aldesleukin (1) · fludarabine (1) · ocrelizumab (1)
Gemma Biotherapeutics (1) · Indapta Therapeutics, INC. (1) · University of Alabama at Birmingham (1)
United States (3) · Brazil (1) · Canada (1) · Israel (1) · Netherlands (1) · United Kingdom (1)
Jonathan McConathy, MD,PhD (1) · May Orfali, MD (1)